Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
About this study
The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.
- Condition
- Mature B-cell Non-Hodgkin Lymphoma
- Tested
- Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone, Drug: Ifosphamide, Etoposide, Methotrexate, Vincris...
- Sponsor
- Children's Cancer Group, China
Who can join
- Age
- Up to 18 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Maximum age: 18 years
- Study condition: Mature B-cell Non-Hodgkin Lymphoma
- Histology or cytologically confirmed mature B-cell NHL/AL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)
- Able to comply with scheduled follow-up and with management of toxicity
- Signed informed consent
Exclusion 6
- Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study
- Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
- Evidence of pregnancy or lactation period. Past or current anti-cancer treatment except corticosteroids during less than one week.
- Tumor cell negative for CD20
- Prior exposure to rituximab
- Hepatitis B carrier status history of HBV or positive serology.
Where
1 site, 1 recruiting
Shanghai Children's Medical Center
Shanghai, Shanghai Municipality, China
Contact
-
Yi-jin Gao
+82064 86-21-38626161 gaoyijin@scmc.com.cn
Potential match only. Final eligibility is determined by the study team.